Advances in developing ACE2 derivatives against SARS-CoV-2
H Zhang, P Lv, J Jiang, Y Liu, R Yan, S Shu… - The Lancet …, 2023 - thelancet.com
Extensive immune evasion of SARS-CoV-2 rendered therapeutic antibodies ineffective in
the COVID-19 pandemic. Propagating SARS-CoV-2 variants are characterised by immune …
the COVID-19 pandemic. Propagating SARS-CoV-2 variants are characterised by immune …
Engineering ACE2 decoy receptors to combat viral escapability
T Arimori, N Ikemura, T Okamoto, J Takagi… - Trends in …, 2022 - cell.com
Decoy receptor proteins that trick viruses to bind to them should be resistant to viral escape
because viruses that require entry receptors cannot help but bind decoy receptors …
because viruses that require entry receptors cannot help but bind decoy receptors …
COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes
SARS-CoV-2 infection can cause persistent respiratory sequelae. However, the underlying
mechanisms remain unclear. Here we report that sub-lethally infected K18-human ACE2 …
mechanisms remain unclear. Here we report that sub-lethally infected K18-human ACE2 …
Molecular insights and optimization strategies for the competitive binding of engineered ACE2 proteins: A multiple replica molecular dynamics study
J Sun, X Liu, S Zhang, M Li, Q Zhang… - Physical Chemistry …, 2023 - pubs.rsc.org
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) continues to spread globally, and rapid viral evolution and the emergence of …
(SARS-CoV-2) continues to spread globally, and rapid viral evolution and the emergence of …
S protein, ACE2 and host cell proteases in SARS-CoV-2 cell entry and infectivity; is soluble ACE2 a two blade sword? A narrative review
R Nejat, MF Torshizi, DJ Najafi - Vaccines, 2023 - mdpi.com
Since the spread of the deadly virus SARS-CoV-2 in late 2019, researchers have restlessly
sought to unravel how the virus enters the host cells. Some proteins on each side of the …
sought to unravel how the virus enters the host cells. Some proteins on each side of the …
A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo
B Havranek, GW Lindsey, Y Higuchi, Y Itoh… - Communications …, 2023 - nature.com
Abstract SARS-CoV-2, especially B. 1.1. 529/omicron and its sublineages, continues to
mutate to evade monoclonal antibodies and antibodies elicited by vaccination. Affinity …
mutate to evade monoclonal antibodies and antibodies elicited by vaccination. Affinity …
Neutrophil elastase decreases SARS-CoV-2 spike protein binding to human bronchial epithelia by clipping ACE-2 ectodomain from the epithelial surface
Patients with cystic fibrosis (CF) have decreased severity of severe acute respiratory
syndrome-like coronavirus-2 (SARS-CoV-2) infections, but the underlying cause is …
syndrome-like coronavirus-2 (SARS-CoV-2) infections, but the underlying cause is …
Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation
The Spike of SARS-CoV-2 recognizes a transmembrane protease, angiotensin-converting
enzyme 2 (ACE2), on host cells to initiate infection. Soluble derivatives of ACE2, in which …
enzyme 2 (ACE2), on host cells to initiate infection. Soluble derivatives of ACE2, in which …
Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides
GN Llewellyn, HY Chen, GL Rogers, X Huang… - Journal of …, 2023 - Am Soc Microbiol
With increasing resistance of SARS-CoV-2 variants to antibodies, there is interest in
developing entry inhibitors that target essential receptor-binding regions of the viral Spike …
developing entry inhibitors that target essential receptor-binding regions of the viral Spike …
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
BD Wines, L Kurtovic, HM Trist, S Esparon… - Frontiers in …, 2022 - frontiersin.org
Joining a function-enhanced Fc-portion of human IgG to the SARS-CoV-2 entry receptor
ACE2 produces an antiviral decoy with strain transcending virus neutralizing activity. SARS …
ACE2 produces an antiviral decoy with strain transcending virus neutralizing activity. SARS …